Monitoring Anti-Dementia Drugs by Serum Levels

NCT04117178 | Completed Phase 4 Results DMC

• 2 other identifiers: REG-007-20182017-002707-10
• Study Type: interventional
• Target: 132
• Locations: 1 country
• Sites: 1

Brief Summary

The main objective of the MONANTI study is twofold: Firstly, to determine the serum concentration (SC) the anti-dementia drugs donepezil and memantine in a broadly defined clinical population of patients suffering from dementia treated with the two drugs in question. Secondly, to determine whether adjustment of treatment of anti-dementia medication based on measurements of the SC will benefit patients in terms of cognitive performance, activities of daily living (ADL), frequency and severity of side effects. The reason for conduction of this study is that the relationship between serum-level of anti-dementia drugs, clinical efficacy, compliance and side effects has only been scarcely investigated. Both a previously published study and a preliminary (pilot)study conducted imply that roughly 50 % of patients on donepezil have SC outside the recommended therapeutic reference range (TRR). Thus, MONANTI will investigate if this is indeed the case in a broadly comprised population of patients with dementia treated with donepezil or memantine. In addition, MONANTI will link SC to co-morbidity, level of compliance, medication interactions. It is hypothesized that the efficacy of anti-dementia drugs can be significantly improved by adjustment of treatment according to SC. Also, it is hypothesized that the burden of side effects can be reduced in patients in whom too high SC are detected, if dose reduction or change of treatment drug is done. MONANTI is a randomized study, in which the assessor is blinded to avoid related biases to the extent possible. To meet the enrollment criteria eligible participants must: A) be newly diagnosed with either Alzheimer's disease dementia, dementia with Lewy-bodies or Parkinson's disease with dementia and B) be scheduled for treatment with either donepezil or memantine. C) not meet a list of (exclusion) criteria, which have been set up in order to avoid blur and biases of the results. D) be able to give written informed consent to participation in presence of a close relative. After enrollment the participants will be randomly assigned to one of two study groups. In the first of these, the control group, the participants receive standard treatment and follow-up at the outpatient clinic. In addition, all participants in the control group who complete the trial will have a blood sample collected at the final visit to measure the SC of the anti-dementia drug along with a genetic test for a few key genes thought to be relevant for the study (two liver enzymes (cyp2D6, cyp3A4/5, APOE-genotype, butyrylcholine-esterase K-variant). In the other group, the intervention group, the participators will be closely monitored for side effects after prescription of anti-dementia drugs. All participants in the intervention group will be offered a measurement of the SC in case they experience drug side effects within 2 months of treatment initiation. All participants in the intervention group will have a measurement of the SC done at the 6 months visit. The measured SC will be compared to the TRR of the drug in question. This information, along with details from the clinical assessment at the 6 month visit will be used to guide the decision of whether or not to adjust treatment. All decisions on treatment adjustment during the trial are done by the PI according to details in the protocol. All participants in the intervention group are evaluated again at a 12 month visit, identical to that of the control groups. To assess the possible effects of SC guided treatment adjustment six clinical tests/rating scales will be used (MMSE, ACE, NPI-Q, DAD, CGI, GDS). The tests/rating scales will be administered both at the enrollement visit and one year later at the final 12 month follow-up visit. To measure the effect of donepezil on brain cholinergic function approx. 30 participants will be recruited for electroencephalography (EEG). These participants will have an EEG done at enrollment and after 12 months. In addition to the above mentioned quantitative study a qualitative study with relatives of enrolled participants is planned. All the needed approvals have been obtained according to Danish law (approval by the Danish Data Protection Agency, Scientific Ethics Committee for Region Sjaelland, The Danish Medical Agencies).

Conditions

Dementia; Dementia With Lewy Bodies; Dementia in Parkinsons Disease; Dementia Alzheimers; Alzheimer Disease

Keywords

Therapeutic Drug Monitoring; TDM; Adverse effects; Dementia; Alzheimer's disease

Outcome Measures

Primary Outcomes (4)

• Change of Mini Mental State Examination (MMSE) Test Result

  Widely used clinical test for brief assesment of cognitive function. Total score ranging from 0 (worst) to 30 (best).

  1 year (enrollment in study and at 1-year follow-up)

• Change of Adenbrooke's Cognitive Examination (ACE) Test Result

  Widely used clinical test for assesment of cognitive function. The total score ranges from 0 (worst) 100 (best) and includes the score of the MMSE test (0-30).

  1 year (enrollment in study and at 1-year follow-up)

• Percentage of Participants With a Serum Concentration Within the Therapeutic Reference Range (TRR) at 12 Month Follow-up Visit.

  Percentage of participans in each group with serum concentrations of the study drugs within the therapeutic reference range (TRR) at the 12 month follow-up visit. According to the 2017 AGNP consensus guidelines the TRRs are "ranges of drug concentrations in blood that specify a lower limit below which a drug induced therapeutic response is relatively unlikely to occur and an upper limit above which tolerability decreases or above which it is relatively unlikely that therapeutic improvement may be still enhanced" (Pharmacopsychiatry . 2018 Jan;51(1-02):9-62. doi: 10.1055/s-0043-116492. Epub 2017 Sep 14). Donepezil has a serum TRR of 50-75 nanograms per milliliter (ng/mL) and memantine has a serum TRR of 90-150 ng/mL.

  Counted at the 12 month visit

• Level of Compliance to Treatment

  The level to which the medication has been ingested as prescribed. Both the participant him/her self is questioned as is the primary relative. The level of compliance is rated as belonging to one of the four categories: 1) 'completely regular drug intake' (no missed daily doses within 6 months), 2 'regular drug intake' (less than 10 missed daily doses within 6 months), 3) 'less regular drug intake' (10 - 30 missed daily doses with 6 months), 4) 'irregular drug intake' (more than 30 missed daily doses within 6 months)

  Level of compliance will be scored at the one year follow-up by both questioning the participant and the primary relative.

Secondary Outcomes (6)

• Change of Clinical Global Impression (CGI) Score Result

  1 year (enrollment in study and at 1-year follow-up)

• Change in Geriatric Depression Scale (GDS) Symptoms Score

  The GDS is administered to all participants at the both the baseline and 12-month follow-up visit.

• Change of Disability Assessment for Dementia (DAD) Score Result

  1 year (enrollment in study and at 1-year follow-up)

• Change of Neuropsychiatric Inventory Questionnaire (NPI-Q) Score Result

  1 year (enrollment in study and at 1-year follow-up)

• C2D6 Phenotype

  For participants in the standard of care arm CYP2D6 status will be determined 1 year after enrollment. For participants in the intervention arm Cyp2D6 will be tested within 2 months if side effects are experienced, if not then after 6 months.

Other Outcomes (1)

• Genetic Test for APOe4 Allele Status.

  For participants who complete the trial APOe4 allele status is assessed at the 1 year visit.

Study Arms (2)

Standard of care

ACTIVE COMPARATOR

Participants allocated to this arm follow the usual routines of the out patient dementia clinic but are requested to have the serum level of the prescribed drug measured after 12 month. Also, CYP2D6, BcHE K and APOe4 status will be determined after 12 months.

Diagnostic Test: Measurement of serum level of anti-dementia drug

Intervention arm

EXPERIMENTAL

Participants allocated to this arm follow are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention arm not experiencing side effects will have their treatment adjusted after 6 months based upon serum level of the drug in question.

Drug: Donepezil; Drug: Memantine; Diagnostic Test: Measurement of serum level of anti-dementia drug

Interventions

Donepezil DRUG

Adjustment of treatment with donepezil according to serum level.

Intervention arm

Memantine DRUG

Adjustment of treatment with memantine according to serum level.

Intervention arm

Measurement of serum level of anti-dementia drug DIAGNOSTIC_TEST

Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question. Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month.

Intervention arm; Standard of care

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• A. Participant must be newly diagnosed with one of the three conditions below
• Alzheimer's disease dementia
• dementia with Lewy Bodies
• Dementia in Parkinson's disease B. Participant must be prescribed either donepezil or memantine at enrollment. C. Participant must be able to give informed consent to participation in the study.

You may not qualify if:

• no accompanying relative at the enrollment and/or follow-up visits
• patients living alone who do not receive help to administer medication.
• lack of ability to cooperate, including severely reduced vision or impaired hearing and/or other severe disabilities.
• patients unable to give informed consent in a meaningful sense due to cognitive decline at enrollment.
• known psychiatric disease (schizophrenia, bipolar affective disorder etc.). However, patients suffering from depression are eligible if they have been in continuously medically treated for at least 3 months prior to enrollment.
• known neurologic disorder, which by it self could contribute to cognitive symptoms.
• other known medical condition (kidney-, liver-, metabolic disease etc.) which by itself could contribute to cognitive symptoms.
• treatment with anti-psychotic drugs within 3 months of possible enrollment. A minimal daily dosage of benzodiazepine is deemed permissable for enrollment.
• patients with a history of substantial previous abuse of alcohol or drugs. Also, any kind of substance abuse within last 3 months.
• any previous severe trauma to the head or neuroinfections which could contribute to cognitive symptoms.
• electro convulsive treatment within last 3 months.
• anesthesia within last 3 months

Sponsors & Collaborators

• Zealand University Hospital: lead
• Filadelfia Epilepsy Hospital: collaborator

Study Sites (1)

Regionalt Videnscenter for Demens

Roskilde, Region Sjælland, 4000, Denmark

Location

Related Publications (1)

• Fischer MHF, Zibrandtsen IC, Johannsen P, Siersma V, Rasmussen JB, Larsen JB, Hogh P. Therapeutic drug monitoring for dose optimization in Alzheimer's disease and in dementia with Lewy bodies: A randomized single-blinded clinical trial. J Alzheimers Dis Rep. 2024 Nov 24;8(1):1516-1528. doi: 10.1177/25424823241289373. eCollection 2024.

  PMID: 40034344 DERIVED

MeSH Terms

Conditions

Dementia; Lewy Body Disease; Alzheimer Disease

Interventions

Donepezil; Memantine

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Mental Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Tauopathies

Intervention Hierarchy (Ancestors)

Indans; Indenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Polycyclic Compounds; Amantadine; Adamantane; Bridged-Ring Compounds

Results Point of Contact

• Title: Michael Fischer
• Organization: Department of Neurology, Zealand University Hospital

mihh@regionsjaelland.dk

+4547322800

Study Officials

• Peter Høgh, MD, ph.d.

  Regionalt Videnscenter for Demens

  PRINCIPAL INVESTIGATOR

• Michael Fischer, MD

  Regionalt Videnscenter for Demens

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Single blinded, randomized study with two arms: 'standard of care' arm and 'intervention' arm. Participants in the intervention arm will have their treatment adjusted according to Serum levels of the anti-dementia drug prescribed.

Study Record Dates

• First Submitted: September 30, 2019
• First Posted: October 7, 2019
• Study Start: February 4, 2020
• Primary Completion: February 16, 2023
• Study Completion: February 16, 2023
• Last Updated: February 10, 2025
• Results First Posted: February 10, 2025

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

DK (1)